Seelos Therapeutics, Inc. NASDAQ:SEEL

Founder-led company
Financial Health
0
1
2
3
4
5
6
7
8
9

Seelos Therapeutics stock price monthly change

-40.41%
month

Seelos Therapeutics stock price quarterly change

+8.55%
quarter

Seelos Therapeutics stock price yearly change

-48.32%
year

Seelos Therapeutics key metrics

Market Cap
214.97K
Enterprise value
98.17M
P/E
-1.22
EV/Sales
N/A
EV/EBITDA
-1.34
Price/Sales
N/A
Price/Book
-8.81
PEG ratio
-0.01
EPS
-5.14
Revenue
1.97M
EBITDA
-37.49M
Income
-27.11M
Revenue Q/Q
-28.34%
Revenue Y/Y
144.30%
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
-1899.44%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Seelos Therapeutics stock price history

Seelos Therapeutics stock forecast

Seelos Therapeutics financial statements

Seelos Therapeutics, Inc. (NASDAQ:SEEL): Profit margin
Jun 2023 336K -29.49M -8778.57%
Sep 2023 406K 10.49M 2585.71%
Dec 2023 653K -5.45M -835.07%
Mar 2024 579K -2.66M -460.1%
Seelos Therapeutics, Inc. (NASDAQ:SEEL): Analyst Estimates
2027 144.9M 0
  • Analysts Price target

  • Financials & Ratios estimates

Seelos Therapeutics, Inc. (NASDAQ:SEEL): Earnings per share (EPS)
2022-11-10 -0.1 -0.18
2023-03-10 -0.22231 -0.17
Seelos Therapeutics, Inc. (NASDAQ:SEEL): Debt to assets
Jun 2023 11889000 59.06M 496.84%
Sep 2023 6218000 36.63M 589.1%
Dec 2023 5418000 38.92M 718.49%
Mar 2024 3612000 36.71M 1016.5%
Seelos Therapeutics, Inc. (NASDAQ:SEEL): Cash Flow
Jun 2023 -5.90M 0 -2.31M
Sep 2023 -5.74M 0 2.49M
Dec 2023 -1.91M 0 2.32M
Mar 2024 -4.64M 0 2.17M

Seelos Therapeutics alternative data

Seelos Therapeutics, Inc. (NASDAQ:SEEL): Employee count
Aug 2023 16
Sep 2023 16
Oct 2023 16
Nov 2023 16
Dec 2023 16
Jan 2024 16
Feb 2024 16
Apr 2024 15
May 2024 15
Jun 2024 10
Jul 2024 10

Seelos Therapeutics other data

24.09% -5.58%
of SEEL is owned by hedge funds
25.55M -5.75M
shares is hold by hedge funds

Seelos Therapeutics, Inc. (NASDAQ:SEEL): Insider trades (number of shares)
Period Buy Sel
Nov 2023 83000 0
Dec 2023 151514 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
MEHRA RAJ director, officer.. Common Stock 75,757 $1.32 $99,999
Purchase
MEHRA RAJ director, officer.. Common Stock Warrant (right to buy) 75,757 $1.32 $99,999
Purchase
GOLEMBIEWSKI MICHAEL JOSEPH officer: Chief Financial Officer
Common Stock 83,000 $1.21 $100,264
Purchase
O'CONNOR DANIEL J. director
Common Stock 16,000 $0.61 $9,792
Purchase
DALESANDRO MARGARET director
Common Stock 35,000 $0.6 $20,965
Purchase
MEHRA RAJ director, officer.. Common Stock 66,667 $0.85 $56,867
Purchase
MEHRA RAJ director, 10 perc.. Common Stock 133,333 $0.75 $100,000
Option
DORSEY BRIAN other: Former SVP, Chief Dev Of..
Common Stock 81,775 N/A N/A
Purchase
DENNER ALEXANDER J 10 percent owner
Warrants to purchase Common Stock 2,835 $8.8 $24,948
Purchase
DENNER ALEXANDER J 10 percent owner
Common Stock 6,104 $1.63 $9,950
Patent
Application
Filling date: 23 Jun 2021 Issue date: 21 Apr 2022
Application
Filling date: 15 Jul 2020 Issue date: 14 Jan 2021
Grant
Filling date: 2 Jul 2019 Issue date: 22 Dec 2020
Grant
Filling date: 31 Jan 2019 Issue date: 25 Aug 2020
Application
Filling date: 2 Jul 2019 Issue date: 12 Dec 2019
Grant
Filling date: 7 May 2014 Issue date: 3 Dec 2019
Application
Filling date: 31 Jan 2019 Issue date: 7 Nov 2019
Thursday, 24 October 2024
prnewswire.com
Tuesday, 15 October 2024
prnewswire.com
Thursday, 26 September 2024
prnewswire.com
Wednesday, 25 September 2024
prnewswire.com
Tuesday, 24 September 2024
prnewswire.com
Monday, 8 July 2024
investorplace.com
Thursday, 16 May 2024
prnewswire.com
Tuesday, 14 May 2024
prnewswire.com
Monday, 29 April 2024
prnewswire.com
Tuesday, 19 March 2024
prnewswire.com
Friday, 26 January 2024
prnewswire.com
Monday, 22 January 2024
prnewswire.com
Tuesday, 9 January 2024
InvestorPlace
Wednesday, 29 November 2023
InvestorPlace
Wednesday, 22 November 2023
PennyStocks
Friday, 27 October 2023
PRNewsWire
Monday, 23 October 2023
PennyStocks
Thursday, 21 September 2023
InvestorPlace
Wednesday, 20 September 2023
Proactive Investors
Market Watch
Wednesday, 6 September 2023
InvestorPlace
Wednesday, 12 July 2023
Seeking Alpha
Friday, 10 February 2023
PRNewsWire
Sunday, 8 January 2023
Seeking Alpha
Thursday, 8 December 2022
PRNewsWire
Tuesday, 6 December 2022
Zacks Investment Research
Friday, 28 October 2022
InvestorPlace
Tuesday, 4 October 2022
Seeking Alpha
Tuesday, 13 September 2022
PennyStocks
Friday, 9 September 2022
PennyStocks
  • When is Seelos Therapeutics's next earnings date?

    Unfortunately, Seelos Therapeutics's (SEEL) next earnings date is currently unknown.

  • Does Seelos Therapeutics pay dividends?

    No, Seelos Therapeutics does not pay dividends.

  • How much money does Seelos Therapeutics make?

    Seelos Therapeutics has a market capitalization of 214.97K. Seelos Therapeutics made a loss 37.88M US dollars in net income (profit) last year or -$0.17 on an earnings per share basis.

  • What is Seelos Therapeutics's stock symbol?

    Seelos Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "SEEL".

  • What is Seelos Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Seelos Therapeutics?

    Shares of Seelos Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Seelos Therapeutics's key executives?

    Seelos Therapeutics's management team includes the following people:

    • Dr. Raj Mehra J.D., Ph.D. Founder, Chairman, Chief Executive Officer & Pres(age: 65, pay: $724,230)
  • Is Seelos Therapeutics founder-led company?

    Yes, Seelos Therapeutics is a company led by its founder Dr. Raj Mehra J.D., Ph.D..

  • How many employees does Seelos Therapeutics have?

    As Jul 2024, Seelos Therapeutics employs 10 workers, which is 33% less then previous quarter.

  • When Seelos Therapeutics went public?

    Seelos Therapeutics, Inc. is publicly traded company for more then 26 years since IPO on 19 Apr 1999.

  • What is Seelos Therapeutics's official website?

    The official website for Seelos Therapeutics is seelostherapeutics.com.

  • Where are Seelos Therapeutics's headquarters?

    Seelos Therapeutics is headquartered at 300 Park Avenue, New York, NY.

  • How can i contact Seelos Therapeutics?

    Seelos Therapeutics's mailing address is 300 Park Avenue, New York, NY and company can be reached via phone at +64 6 293 2100.

Seelos Therapeutics company profile:

Seelos Therapeutics, Inc.

seelostherapeutics.com
Exchange:

NASDAQ

Full time employees:

8

Industry:

Biotechnology

Sector:

Healthcare

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.

300 Park Avenue
New York, NY 10022

CIK: 0001017491
ISIN: US81577F2083
CUSIP: 81577F109